Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
BACKGROUND
ProPSA has been suggested for the detection of preferentially aggressive prostate cancer (PCa). We report on the use of proPSA and free PSA to enhance preoperative staging and grading.


METHODS
Serum samples from 376 PCa patients within the PSA range 1-25 microg/l who underwent radical prostatectomy were analysed for PSA, free PSA (fPSA) and (-5, -7) proPSA.


RESULTS
ProPSA was only significantly different between pT2 and pT3 PCa (p = 0.02) in the subgroup of patients with % fPSA < 10%. The ratio proPSA/% fPSA differed between G2 and G3 (p = 0.004), Gleason < 7 and Gleason > or =7 (p = 0.001), and pT2 and pT3 tumors (p < 0.0001) at PSA 1-25 microg/l. However, % fPSA improved differentiation only between Gleason < 7 and Gleason > or = 7 tumors, not between pT2 and pT3 or G2 and G3 tumors.


CONCLUSIONS
ProPSA as a single parameter did not improve the detection of non-organ confined or aggressive PCa whereas proPSA/% fPSA further improved staging and grading within all analysed PSA ranges.
Stephan
Carsten
C
Departments of Neurology, Universitätsmedizin Charité Berlin, CCM, Germany. carsten.stephan@charite.de
Meyer
Hellmuth-Alexander
HA
Paul
Eva-Maria
EM
Kristiansen
Glen
G
Loening
Stefan A
SA
Lein
Michael
M
Jung
Klaus
K
D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D011498:Protein Precursors / Q000097:blood* / Q000378:metabolism; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D011498:Protein Precursors; D017430:Prostate-Specific Antigen